Business
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes.
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Cryogenic flow control enhances the efficacy and precision of cryoablation procedures","length":85,"tagName":"p","attribs":{}},{"type":"text","content":"Robust IP portfolio becomes increasingly strategic as global interest in IceCure's platform and next-generation cryoablation technologies grows following ProSense®'s recent FDA marketing authorization in low-risk breast cancer","length":234,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, Dec. 5, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced it received a Notice of Allowance for a patent from the China National Intellectual Property Administration for its invention titled "Cryogen Flow Control" which relates to its next-generation XSense™ cryoablation system and probes.","length":549,"tagName":"p"},{"type":"image","alt":"IceCure_Medical_Logo","displaySize":"","headline":null,"caption":"IceCure_Medical_Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":"A patent for this invention has been granted in Japan and is currently pending approval in the European Union, the U.S., and other major markets.","length":145,"tagName":"p"},{"type":"text","content":""We believe IceCure's commitment to technology innovation and our drive to make a significant impact on patient outcomes has resulted in our intellectual property portfolio in cryoablation reaching 55 patents granted and allowed across the globe," said Eyal Shamir, IceCure's Chief Executive Officer. "Our cryoablation systems and probes already have regulatory approval in China for indications including breast cancer, and we continue to innovate next-generation liquid nitrogen-based systems including XSense™ to further improve patient outcomes."","length":578,"t...